Loss of Imprinting of Insulin-Like Growth Factor-II (IGF2) Gene in Distinguishing Specific Biologic Subtypes of Wilms Tumor
Open Access
- 21 November 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 93 (22) , 1698-1703
- https://doi.org/10.1093/jnci/93.22.1698
Abstract
Background: Loss of imprinting (LOI) of the insulin-like growth factor-II (IGF2) gene, an epigenetic alteration associated with expression of the normally silent maternal allele, was observed first in Wilms tumor. Although LOI has subsequently been detected in most adult tumors, the biologic role of LOI in cancer remains obscure. We analyzed the imprinting status of Wilms tumors with respect to pathologic subtype, stage, and patient's age at diagnosis and examined the expression of genes potentially affected by LOI. Methods: Of 60 Wilms tumors examined, 25 were informative for an ApaI polymorphism in the IGF2 gene, allowing analysis of allele-specific gene expression, and could be classified by pathologic subtype. Gene expression was measured quantitatively by real-time polymerase chain reaction, and pathologic analysis was blinded for genetic status. All statistical tests were two-sided. Results: We observed LOI of IGF2 in nine (90%) of 10 Wilms tumors classified as having a pathologic subtype associated with a later stage of renal development and in only one (6.7%) of 15 Wilms tumors with a pathologic subtype associated with an earlier stage of renal development (P<.001). LOI was associated with a 2.2-fold increase (95% confidence interval [CI] = 1.6-fold to 3.1-fold) in IGF2 expression (P<.001). Children whose Wilms tumors displayed LOI of IGF2 were statistically significantly older at diagnosis (median = 65 months; interquartile range [IQR] = 47–83 months) than children whose tumors displayed normal imprinting (median = 24 months; IQR = 13–35 months; P<.001). Conclusions: These data demonstrate a clear relationship between LOI and altered expression of IGF2 in Wilms tumors and provide a molecular basis for understanding the divergent pathogenesis of this cancer. Analysis of LOI could provide a valuable molecular tool for the classification of Wilms tumor.Keywords
This publication has 27 references indexed in Scilit:
- Insulin-like Growth Factor-II as a Paracrine Growth Factor in Human Neuroblastoma CellsExperimental Cell Research, 1995
- IGF‐2 autocrine stimulation in tumorigenic clones of a human colon‐carcinoma cell lineInternational Journal of Cancer, 1995
- Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomataJournal of Clinical Endocrinology & Metabolism, 1995
- Loss of imprinting in choriocarcinomaNature Genetics, 1995
- Blockade of the insulin‐like growth‐factor‐I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF‐II‐mediated autocrine loopInternational Journal of Cancer, 1994
- Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II)European Journal Of Cancer, 1993
- Relaxation of imprinted genes in human cancerNature, 1993
- Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumourNature, 1993
- Insulin-Like Growth Factor-II: Possible Local Growth Factor in Pheochromocytoma*Journal of Clinical Endocrinology & Metabolism, 1990
- Insulin-Like Growth Factor-ll (IGF-II): A Potential Autocrine/Paracrine Growth Factor for Human Breast Cancer Acting via the IGF-I ReceptorMolecular Endocrinology, 1989